270 related articles for article (PubMed ID: 16650397)
1. Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients.
Ivanović V; Demajo M; Krtolica K; Krajnović M; Konstantinović M; Baltić V; Prtenjak G; Stojiljković B; Breberina M; Nesković-Konstantinović Z; Nikolić-Vukosavljević D; Dimitrijević B
Clin Chim Acta; 2006 Sep; 371(1-2):191-3. PubMed ID: 16650397
[TBL] [Abstract][Full Text] [Related]
2. Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer.
Tsushima H; Ito N; Tamura S; Matsuda Y; Inada M; Yabuuchi I; Imai Y; Nagashima R; Misawa H; Takeda H; Matsuzawa Y; Kawata S
Clin Cancer Res; 2001 May; 7(5):1258-62. PubMed ID: 11350892
[TBL] [Abstract][Full Text] [Related]
3. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
Lipton A; Ali SM; Leitzel K; Demers L; Evans DB; Hamer P; Brown-Shimer S; Pierce K; Carney W
Cancer; 2007 May; 109(10):1933-9. PubMed ID: 17407159
[TBL] [Abstract][Full Text] [Related]
4. Circulating levels of transforming growth factor-βeta (TGF-β) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer.
Divella R; Daniele A; Savino E; Palma F; Bellizzi A; Giotta F; Simone G; Lioce M; Quaranta M; Paradiso A; Mazzocca A
Anticancer Res; 2013 Apr; 33(4):1491-7. PubMed ID: 23564790
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer.
Wakefield LM; Letterio JJ; Chen T; Danielpour D; Allison RS; Pai LH; Denicoff AM; Noone MH; Cowan KH; O'Shaughnessy JA
Clin Cancer Res; 1995 Jan; 1(1):129-36. PubMed ID: 9815895
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
[TBL] [Abstract][Full Text] [Related]
7. Serum level of transforming growth factor-beta1 (TGF-beta1) and the expression of TGF-beta receptor type II in peripheral blood mononuclear cells in patients with autoimmune hepatitis.
Sakaguchi K; Kitano M; Nishimura M; Senoh T; Ohta T; Terao M; Shinji N; Koide N; Tsuji T
Hepatogastroenterology; 2004; 51(60):1780-3. PubMed ID: 15532825
[TBL] [Abstract][Full Text] [Related]
8. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1.
Qian B; Katsaros D; Lu L; Preti M; Durando A; Arisio R; Mu L; Yu H
Breast Cancer Res Treat; 2009 Sep; 117(1):131-40. PubMed ID: 18932017
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of transforming growth factor beta1 are significantly correlated with venous invasion in patients with gastric cancer.
Lin Y; Kikuchi S; Obata Y; Yagyu K;
J Gastroenterol Hepatol; 2006 Feb; 21(2):432-7. PubMed ID: 16509870
[TBL] [Abstract][Full Text] [Related]
10. Changes in plasma transforming growth factor beta in response to high-dose chemotherapy for stage II breast cancer: possible implications for the prevention of hepatic veno-occlusive disease and pulmonary drug toxicity.
Murase T; Anscher MS; Petros WP; Peters WP; Jirtle RL
Bone Marrow Transplant; 1995 Feb; 15(2):173-8. PubMed ID: 7773206
[TBL] [Abstract][Full Text] [Related]
11. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival.
Singhal H; Bautista DS; Tonkin KS; O'Malley FP; Tuck AB; Chambers AF; Harris JF
Clin Cancer Res; 1997 Apr; 3(4):605-11. PubMed ID: 9815727
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma.
Ghellal A; Li C; Hayes M; Byrne G; Bundred N; Kumar S
Anticancer Res; 2000; 20(6B):4413-8. PubMed ID: 11205281
[TBL] [Abstract][Full Text] [Related]
13. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
[TBL] [Abstract][Full Text] [Related]
14. Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma.
Okumoto K; Hattori E; Tamura K; Kiso S; Watanabe H; Saito K; Saito T; Togashi H; Kawata S
Liver Int; 2004 Feb; 24(1):21-8. PubMed ID: 15101997
[TBL] [Abstract][Full Text] [Related]
15. Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.
Souder C; Leitzel K; Ali SM; Demers L; Evans DB; Chaudri-Ross HA; Hackl W; Hamer P; Carney W; Lipton A
Cancer; 2006 Nov; 107(10):2337-45. PubMed ID: 17048231
[TBL] [Abstract][Full Text] [Related]
16. Localization of recognition site between transforming growth factor-beta1 (TGF-beta1) and TGF beta receptor type II: possible implications in breast cancer.
Ivanović V; Demajo M; Todorović-Raković N; Nikolić-Vukosavljević D; Nesković-Konstantinović Z; Krtolica K; Veljković V; Prljić J; Dimitrijević B
Med Hypotheses; 2004; 62(5):727-32. PubMed ID: 15082097
[TBL] [Abstract][Full Text] [Related]
17. Serum concentrations of transforming growth factor-beta 1 in patients with benign and malignant prostatic diseases.
Wolff JM; Fandel TH; Borchers H; Jakse G
Anticancer Res; 1999; 19(4A):2657-9. PubMed ID: 10470214
[TBL] [Abstract][Full Text] [Related]
18. Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia.
Gora-Tybor J; Blonski JZ; Robak T
Mediators Inflamm; 2003 Jun; 12(3):167-71. PubMed ID: 12857600
[TBL] [Abstract][Full Text] [Related]
19. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
20. Serum big endothelin-1 levels in female patients with breast cancer.
Yildirim Y; Gunel N; Coskun U; Sancak B; Bukan N; Aslan S; Cetin A
Int Immunopharmacol; 2008 Aug; 8(8):1119-23. PubMed ID: 18550016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
